NDAINJECTIONINJECTABLE
Approved
Dec 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
LINCOCIN (lincomycin hydrochloride) by Pfizer is mechanism of action lincomycin inhibits bacterial protein synthesis by binding to the 23s rna of the 50s subunit of the bacterial ribosome. Approved for the treatment of serious infections due to susceptible strains of streptococci, pneumococci, staphylococci and 2 more indications. First approved in 1964.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LINCOCIN (lincomycin hydrochloride) is an injectable small-molecule antibiotic approved in 1964 that treats serious bacterial infections caused by streptococci, pneumococci, and staphylococci by inhibiting bacterial protein synthesis. It binds to the 50S ribosomal subunit and is bacteriostatic, halting bacterial growth rather than killing organisms directly.
LOE Approaching
With LOE approaching and minimal recent spending data, the brand team is likely in maintenance mode with limited headcount and focus on market defense rather than growth initiatives.
Mechanism of Action
Mechanism of Action Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro .
Worked on LINCOCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.